AlphaGenome Atlas: Mapping Every Possible DNA Variant
Google DeepMind’s AlphaGenome Atlas maps all nine billion possible DNA variants, helping researchers rapidly prioritise disease-linked mutations.
Machine Learning in Drug Discovery: Gains and Data Gaps
Machine learning in drug discovery promises faster drug screening and fewer failures, but weak data limits gains. See what the latest 2026 review means for pharma.
AI Biology: What Biohub’s $1.8bn Push Means for Pharma
In one of the most important developments, AI biology gets a $1.8 billion boost as Biohub, DOE, and the NIH build open and AI-ready data for virtual cell models.
Real-Time Clinical Trials Are a Huge Competitive Advantage
Real-time clinical trials enable continuous data capture and faster decisions, improving how data is used in clinical trials. Here is what pharma leaders need to know.
Operation TrialBlazer: Can the U.S. Reclaim Clinical Trial Leadership?
Operation TrialBlazer aims to reignite U.S. clinical development by accelerating trials, modernising FDA oversight, and strengthening pharmaceutical innovation.
The Latest Evidence on Informed Consent in Clinical Trials
A recent systematic review reveals incredible detail about informed consent in clinical trials, participant understanding, and trial quality. Find out now.